



FOR IMMEDIATE RELEASE

## **Veeva SiteVault Free Now Available to Simplify Study Execution at Clinical Research Sites**

*Sites now have access to a free eRegulatory application  
to simplify regulatory compliance and speed study execution*

**BARCELONA, Spain — 8 Jan, 2020 — Veeva Systems** (NYSE:VEEV) today announced the availability of **Veeva SiteVault Free**, a free eRegulatory solution for clinical research sites. Veeva SiteVault replaces manual and paper-based regulatory processes by providing a modern cloud application to manage investigator site files in compliance with 21 CFR Part 11 and HIPAA requirements. With SiteVault Free, all sites now have access to advanced technology that reduces administrative burden and speeds study execution.

“As a private practice with multiple clinic research sites, we needed an eRegulatory solution to reduce the time and effort of managing regulatory binders,” said Diane Kachel, clinical research manager at Minnesota Urology. “Veeva SiteVault Free gives us a high-quality, free cloud solution to access, file, and search regulatory documents easier and maintain compliance with less burden.”

Veeva SiteVault simplifies regulatory document management and processes with capabilities such as electronic signatures, remote monitoring, certified copy workflows, and reporting. The application can be used for all trials regardless of what technology sponsors are using, as well as the site file for investigator-initiated trials.

Veeva SiteVault Free supports an unlimited number of studies, documents, and users and comes with customer support. SiteVault is also available in an enterprise edition, which is fully configurable and includes open APIs for integrations, customized reports, and tailored workflows. Veeva SiteVault is built on the proven clinical operations technology used by more than 200 sponsors, including 12 of the top 20 global biopharma companies.

“Veeva is committed to simplifying clinical trial execution for sites, who are a critical part of the discovery and development process,” said Bree Burks, vice president of site strategy at Veeva and a former clinical research director. “Veeva SiteVault reduces the workload of investigators and coordinators so they can focus on important research and get life-changing treatments to patients faster.”

In other news today, Veeva introduced **Veeva Vault Payments**, new add-on application for **Veeva Vault CTMS** that enables sponsors and CROs to speed payments and reimbursements to clinical research sites. Read today's Vault Payments [press release](#) to learn more.

Clinical research sites can sign up for Veeva SiteVault Free now at [sites.veeva.com](https://sites.veeva.com). Learn how Veeva SiteVault Free reduces administrative burden for sites by watching an on-demand webinar at [veeva.com/SiteVaultFreeWebinar](https://veeva.com/SiteVaultFreeWebinar). Also, read how **University of Louisville** is using Veeva SiteVault Enterprise to automate trial processes and document management.

### **Additional Information**

For more on Veeva SiteVault, visit: [sites.veeva.com](https://sites.veeva.com)

Connect with Veeva on LinkedIn: [linkedin.com/company/veeva-systems](https://linkedin.com/company/veeva-systems)

Follow @veeva\_eu on Twitter: [twitter.com/veeva\\_eu](https://twitter.com/veeva_eu)

Like Veeva on Facebook: [facebook.com/veevasystems](https://facebook.com/veevasystems)

### **About Veeva Systems**

Veeva Systems Inc. is the leader in cloud-based software for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 800

customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. Veeva is headquartered in the San Francisco Bay Area, with offices throughout North America, Europe, Asia, and Latin America. For more information, visit [veeva.com/eu](http://veeva.com/eu).

### **Forward-looking Statements**

This release contains forward-looking statements, including the market demand for and acceptance of Veeva's products and services, the results from use of Veeva's products and services, and general business conditions, particularly in the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva's historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva's expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva's financial results are included under the captions, "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations," in the company's filing on Form 10-Q for the period ended October 31, 2019. This is available on the company's website at [veeva.com](http://veeva.com) under the Investors section and on the SEC's website at [sec.gov](http://sec.gov). Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.

###

### **Contact:**

Roger Villareal  
Veeva Systems  
925-264-8885  
[roger.villareal@veeva.com](mailto:roger.villareal@veeva.com)

Kiran May  
Veeva Systems  
+44-796-643-2912  
[kiran.may@veeva.com](mailto:kiran.may@veeva.com)